What is MaxCyte's cash & equivalents?

MaxCyte (MXCT) reported cash & equivalents of $14.56M in Q1 2026.

How has MaxCyte's cash & equivalents changed year-over-year?

MaxCyte's cash & equivalents decreased by 37.8% year-over-year, from $23.39M to $14.56M.

What is the long-term trend for MaxCyte's cash & equivalents?

Over 5 years (2020 to 2025), MaxCyte's cash & equivalents has grown at a 1.4% compound annual growth rate (CAGR), from $18.76M to $20.07M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

MaxCyte MXCT Cash & Equivalents

Cash & Equivalents at other companies

Bio-Rad LaboratoriesBIO

$509M-2.7%

Thermo Fisher ScientificTMO

$3.28B-21.4%

Ginkgo BioworksDNA

$188.67M-46.9%

Immix Biopharma, Inc.IMMX

$79.25M+398%

Rapid Micro BiosystemsRPID

$14.1M-26.8%

PDE

Pro-Dex, Inc.PDEX

$9.99M+123%

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's cash & equivalents?: MaxCyte (MXCT) reported cash & equivalents of $14.56M in Q1 2026.
How has MaxCyte's cash & equivalents changed year-over-year?: MaxCyte's cash & equivalents decreased by 37.8% year-over-year, from $23.39M to $14.56M.
What is the long-term trend for MaxCyte's cash & equivalents?: Over 5 years (2020 to 2025), MaxCyte's cash & equivalents has grown at a 1.4% compound annual growth rate (CAGR), from $18.76M to $20.07M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.